February 15, 2013
Bio-NEMS Corporation announced a strategic partnership and technology development agreement with In-Q-Tel (IQT) to accelerate commercialization of its rapid handheld DNA testing technology. IQT, based in Arlington, VA, is the independent strategic investment firm that identifies, adapts, and delivers technologies that support the missions of the U.S. Intelligence Community.
Bio-NEMS has developed proprietary, interdisciplinary innovations to enable DNA to be directly analyzed on the surface of a semiconductor device. This breakthrough capability is expected to enable DNA analysis in 5 minutes or less from a battery-powered device that can be operated by almost anyone.
“Our semiconductor-based approach enables low cost, digital accurate analysis for even the most challenging DNA/RNA applications such as human identification, oncology, non-invasive prenatal diagnostics and epigenetics,” says David Medin, CEO. “This technology has the potential to revolutionize law enforcement, security and medical diagnostics. The In-Q-Tel investment will help us to accelerate the commercialization of this much needed technology.”
“The semiconductor-based technology being developed by Bio-NEMS represents a step forward in the field of DNA and RNA analysis,” said Syd Ulvick, Senior Vice President in charge of Physical and Biological Technologies at IQT. “IQT is excited to help facilitate its continued development for both the commercial and government markets.”
Bio-NEMS is an emerging technology company based in Menlo Park, CA. The company has proprietary, interdisciplinary innovations to enable DNA to be directly analyzed on the surface of a high-speed, custom semiconductor device. The DNA sequencing market achieved a 1000-fold decrease in cost and analysis time by replacing electrophoresis-based analysis with semiconductor-based analysis. Bio-NEMS is expected to be the first company to use semiconductor-based analysis to drive DNA testing into the portable realm. For more information visit www.bio-nems.com